A detailed history of Neuberger Berman Group LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Neuberger Berman Group LLC holds 3,874 shares of CYTK stock, worth $193,157. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,874
Previous 95,366 95.94%
Holding current value
$193,157
Previous $5.17 Million 96.05%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$51.22 - $60.16 $4.69 Million - $5.5 Million
-91,492 Reduced 95.94%
3,874 $204,000
Q2 2024

Nov 14, 2024

BUY
$47.86 - $75.05 $831,041 - $1.3 Million
17,364 Added 22.26%
95,366 $5.17 Million
Q2 2024

Aug 13, 2024

BUY
$47.86 - $75.05 $831,041 - $1.3 Million
17,364 Added 22.26%
95,366 $5.17 Million
Q1 2024

Nov 14, 2024

BUY
$63.75 - $108.06 $1.07 Million - $1.81 Million
16,779 Added 27.41%
78,002 $5.47 Million
Q1 2024

May 13, 2024

BUY
$63.75 - $108.06 $4.97 Million - $8.43 Million
78,002 New
78,002 $5.47 Million
Q4 2023

Nov 14, 2024

SELL
$26.88 - $83.49 $917,763 - $2.85 Million
-34,143 Reduced 35.8%
61,223 $5.11 Million
Q4 2023

Feb 09, 2024

BUY
$26.88 - $83.49 $369,035 - $1.15 Million
13,729 Added 28.91%
61,223 $5.11 Million
Q3 2023

Nov 14, 2023

BUY
$29.46 - $36.61 $62,101 - $77,173
2,108 Added 4.64%
47,494 $1.4 Million
Q2 2023

Aug 11, 2023

BUY
$32.62 - $40.75 $725,044 - $905,750
22,227 Added 95.98%
45,386 $1.48 Million
Q1 2023

May 12, 2023

BUY
$33.36 - $45.71 $772,584 - $1.06 Million
23,159 New
23,159 $814,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.69B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.